See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

HLX-43, a next-generation PD-L1-targeting antibody-drug conjugate

Oct. 27, 2023
There is a need for new agents targeting PD-1/PD-L1 because many patients either do not respond or develop resistance to treatment.
BioWorld Science Conferences Regulatory European Society for Medical Oncology Cancer Antibody-drug conjugate Immuno-oncology IND NMPA